Le Lézard
Classified in: Health, Science and technology
Subjects: TRI, FDA

Ascentage Pharma to Initiate Phase Ib Study of HQP1351 in Tyrosine Kinase Inhibitors -resistant Chronic Myeloid Leukemia Patients in the US

SUZHOU, China and ROCKVILLE, Md., July 21, 2019 /PRNewswire/ -- Ascentage Pharma, a globally-focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, hepatitis B virus and age-related diseases, today announced that the company was notified by the U.S. Food & Drug Administration (FDA) on the clearance of the Investigational New Drug (IND) application which allows the company to initiate its Phase Ib clinical trial of HQP1351, a novel drug candidate developed by Ascentage Pharma, for the treatment of patients with tyrosine kinase inhibitors (TKI)-resistant chronic myeloid leukemia (CML) in the United States.


HQP1351 is the sixth molecule to receive clearance of IND from the FDA for Ascentage Pharma. The Company submitted data generated from over 100 subjects in the Phase I clinical trial in China to the FDA to support the IND application.

This clinical study is a bridging Phase Ib clinical trial with three dose cohorts (30mg, 40mg and 50mg), which is more efficient than the traditional 3+3 dose-escalation study and is expected to accelerate the progress of this clinical trial. It is designed to evaluate the safety, tolerability, and pharmacokinetic (PK) of HQP1351 in CML patients who are resistant or intolerant to at least second-line TKIs and to confirm the recommended Phase II dose (RP2D). This clinical study will be led by Hagop Kantarjian, M.D., Chair of Department of Leukemia at MD Anderson Cancer Center, and other prominent US research centers and hospitals will also participate.

HQP1351 is designed to address the acquired drug resistance from the treatment using Imatinib. Such resistance is developed in 20-30% of patients treated with the drug develop acquired drug resistance, thus representing a major challenge to the treatment of CML. HQP1351 is an oral, third-generation BCR-ABL TKI targeting a broad spectrum of BCR-ABL mutants, including those with the T315I mutation, to treat drug-resistant CML patients. The agent is currently in pivotal Phase II clinical trial and is the first third-generation BCR-ABL inhibitor targeting drug-resistant CML in China. A New Drug Application (NDA) submission is planned upon the successful completion of the pivotal Phase II clinical studies in China.

As previously announced, the updated data from HQP1351 Phase I study in China was accepted as an oral presentation at the 60th American Society of Hematology (ASH) Annual Meeting last December. The preliminary data showed that HQP1351 was effective in the treatment of first and second generation TKI-resistant CML, especially the highly resistant CML with T315I mutation, with improved safety profile compared to other agents in the same class. This result demonstrates HQP1351's best-in-class potential for treating TKI-resistant CML.

Dr. Yifan Zhai, Chief Medical Officer of Ascentage Pharma, commented: "Ascentage Pharma used the clinical data from its HQP1351 Phase1 clinical trial in China to support the US IND application. This FDA agreed Phase Ib clinical trial design could significantly accelerate HQP1351's global clinical development program. Drug-resistant CML represents significant unmet clinical need and we hope that HQP1351 will soon benefit patients worldwide."

About HQP1351
HQP1351 is a novel kinase inhibitor developed by Ascentage Pharma. It is an oral third-generation BCR-ABL inhibitor targeting a broad spectrum of BCR-ABL mutants, including those with the T315I mutation, to treat drug-resistant CML patients. A Phase I clinical trial for patients with TKI-resistant CML has been completed and a pivotal Phase II clinical trial was initiated in China. It also entered a Phase I trial in patients with GIST in China.

About Ascentage Pharma Pharma 
Ascentage Pharma is a globally-focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, hepatitis B virus and age-related diseases. The Company focuses on developing therapeutics that inhibit protein-protein interactions to restore apoptosis, or programmed cell death. Ascentage Pharma has built a pipeline of eight drug candidates in clinical development, including a novel, highly potent Bcl-2/Bcl-xL inhibitor, as well as candidates aimed at IAP and MDM2-p53 pathways, and next-generation tyrosine kinase inhibitors.

SOURCE Ascentage Pharma

These press releases may also interest you

at 08:50
HealthCare Royalty Partners ("HCR"), a global healthcare investment firm, today announced the appointment of two life sciences industry veterans, William M. Burns and Mardi C. Dier, to the firm's Senior Advisor Board. "We are pleased to welcome...

at 08:46
Upscale brands, historic landmarks, and high-end properties alike are turning to the Astreea pedal hand sanitizer dispenser to help protect their guests. With its modern, brushed steel design, Astreea complements its surroundings while its...

at 08:42
Allgress announced today that Info Security Products Guide, the industry's leading information security research and advisory guide, has named Allgress Insight Risk Management Suite (IRMS), a Gold winner in the 16th Annual 2020 Info Security PG's...

at 08:40
Pet King Brands, Inc., the leading manufacturer of over-the-counter animal health care products and the maker of the best-selling ZYMOX® Dermatology and Oratene® Brushless Dental Care products for small and large animals, announced it has partnered...

at 08:40
LEXINGTON, Mass., July 7, 2020  Cyteir Therapeutics, a leader in the discovery and development of next-generation synthetic lethal therapies for cancer, today announced continued progress in their Phase 1/2 clinical study evaluating the company's...

at 08:39
We are now gaining an understanding of the impact of this global pandemic. Infection rate drives the need for better data collection, analysis and reporting in real-time.  Addressing contamination control for our healthcare facilities becomes ground...

News published on 21 july 2019 at 19:00 and distributed by: